Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of VTE Prophylaxis in TBI
NCT03081169Phase 4Withdrawn
- Sponsor
- Loyola University Chicago
- Start
- Apr 2017
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of heparin and enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Loyola University Chicago. Primary endpoint: Venous Thromboembolism. Planned start Apr 2017; status: withdrawn.
02
Drugs
heparinenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03081169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081169.